VALANX Biotech (VALANX), a biotech firm creating novel expertise for site-specific protein conjugation in drug discovery, as we speak introduced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside. The newly fashioned SAB will present unbiased scientific and strategic steerage, bridging the hole between analysis and scientific software to advance the Firm’s antibody-drug conjugate (ADC) packages together with VLX-ADC-001, a LIV-1 focusing on ADC supposed for metastatic triple-negative-breast most cancers for which lead candidate choice is anticipated for June 2026. The SAB’s CMC experience may even help in bringing the Firm’s GoldenSite™ expertise in the direction of GMP manufacturing.
John Lambert PhD is a number one professional in ADC discovery and improvement, with specific experience in ADC biology, payload/linker expertise and translational methods in oncology. Previous to establishing as an unbiased marketing consultant, he was Govt Vice President and Distinguished Analysis Fellow at ImmunoGen, having beforehand served the corporate as Chief Scientific Officer and Chief Regulatory Officer, and holding varied roles throughout biochemistry, course of improvement, manufacturing, and high quality. Dr Lambert is a Fellow of the American Institute for Medical and Organic Engineering, recipient of the World ADC Award for Longstanding Contributions to the Subject, and is Honorary Professor of Queen’s College, Belfast, UK.
Morris Rosenberg PhD is a number one professional and biopharmaceutical marketing consultant with over 25 years of expertise in biologics improvement, manufacturing and commercialization. He held tenures at Biogen and Eli Lilly earlier than becoming a member of Seattle Genetics as Govt Vice President Course of Sciences, the place he constructed the scientific and business provide chain for antibodies and ADCs, serving to set up the corporate as a business biopharmaceutical enterprise with a robust ADC portfolio. As Chief Technical Officer at Immunomedics, he oversaw the launch of Trodelvy for third line triple unfavourable breast most cancers. Throughout his profession, he has been concerned within the improvement and launch of an extra 5 accredited therapies, together with Adcetris, Avonex, Angiomax, Xigris and Forteo.
Peter de Waele PhD is a number one professional in immuno-oncology, superior therapeutics, and biotech innovation, with an extended observe document in translating revolutionary science into early-stage scientific packages. He has been consulting the trade since 2006 with a concentrate on product improvement, regulatory affairs, and mental property. Previous to that, he served as Vice President of R&D and Mental Property and CSO at Celyad and held senior roles at Cryo Save, together with Accountable Particular person for his or her European actions and Regulatory/High quality Director. His earlier profession consists of government positions equivalent to Chief Expertise Officer at CellTran and Chief Working Officer at XCELLentis, the place he oversaw the event of ATMPs and a number of other multi-center worldwide Section I, II and III scientific trials. He started his trade profession in 1986 at Innogenetics, lastly as Chief Therapeutics Officer creating a number of biologicals, together with vaccines, and main the Cell Remedy Enterprise Unit.
Dr John Lambert, Chair of the Scientific Advisory Board, at VALANX Biotech, added: “GoldenSite has robust potential to help the event of next-generation ADC therapeutics by addressing a long-standing toxicity problem by way of site-selective conjugation, unlocking larger efficacy. The staff at VALANX has developed a transparent and credible technique across the platform, and I sit up for working with them.”
Michael Lukesch, Founder and Chief Govt Officer at VALANX Biotech, commented: “Establishing our SAB is a vital subsequent step and milestone for VALANX. As we advance differentiated ADC property and our GoldenSite platform in the direction of the clinic, the experience of the Scientific Advisory Board can be instrumental in shaping our asset technique and positioning throughout the wider ADC discipline. I’m wanting ahead to working with these distinguished specialists in ADC improvement.”
We’re delighted to welcome John, Morris and Peter to the Firm. At this stage of our improvement, appointing main ADC improvement specialists with this depth of expertise offers us robust confidence in our potential to navigate advanced improvement challenges and advance the event of best-in-class therapeutics. We sit up for their steerage as we progress our lead program and construct a pipeline to deal with unmet medical wants in oncology.”
Dr Klaus Orlinger, Chief Scientific Officer, VALANX Biotech
